Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Promyelocytic Leukemia
53%
Hematologic Malignancy
46%
Chemotherapy
44%
Disease
43%
Diffuse Large B Cell Lymphoma
41%
Infection
39%
Overall Survival
33%
Remission
32%
Myelodysplastic Syndrome
24%
Arsenite
23%
Minimal Residual Disease
22%
Nucleophosmin
21%
Retinoic Acid
21%
Decitabine
21%
Rituximab
18%
Mortality Rate
17%
Leukemia
17%
Comorbidity
17%
Coronavirinae
16%
Clinical Trial
15%
Prematurity
14%
Antiapoptotic
14%
Alemtuzumab
14%
Anthracycline
13%
Vaccination Policy
13%
Flow Cytometry
12%
Monoclonal Antibody
11%
Malignant Neoplasm
10%
Acute Leukemia
9%
Adavosertib
9%
Mitoxantrone
9%
Prednisone
9%
Chronic Lymphatic Leukemia
9%
Multiple Sclerosis
8%
SARS Coronavirus
8%
6 Diazo 5 Oxonorleucine
8%
Bispecific Antibody
7%
Hepatitis C
7%
Phosphatidylinositol 4 Phosphate Kinase
7%
Cytotoxicity
7%
Intercellular Adhesion Molecule 1
7%
Estrogen Receptor Beta
7%
Buformin
7%
Splenic Marginal Zone Lymphoma
7%
Ascorbic Acid
7%
Dysproteinemia
7%
Immunoblastic Lymphadenopathy
7%
Pemphigus vulgaris
7%
Nirmatrelvir
7%
Medicine and Dentistry
Acute Myeloid Leukemia
88%
COVID-19
64%
Acute Promyelocytic Leukemia
44%
Hematologic Malignancy
36%
Minimal Residual Disease
31%
Overall Survival
30%
Diffuse Large B-Cell Lymphoma
28%
Decitabine
28%
Infection
25%
Disease
25%
Arsenic Trioxide
22%
Tretinoin
19%
Reverse Transcription Polymerase Chain Reaction
19%
Flow Cytometry
16%
Myelodysplastic Syndrome
16%
Nucleophosmin
16%
DNA Damage
16%
Hematology
15%
Rituximab
15%
Clinical Trial
15%
Lymphocyte
15%
Granulocyte
14%
Prematurity
14%
Molecular Diagnosis
14%
Pemphigus vulgaris
14%
Splenic Marginal Zone Lymphoma
14%
Capillary Electrophoresis
14%
NPM1
14%
Phagocytosis
14%
B Cell
12%
Mitochondrial Respiration
12%
Anthracycline
12%
Leukemia
12%
Monoclonal Antibody
11%
Mortality Rate
11%
Diagnosis
11%
Hypomethylating Agent
10%
CHOP
10%
Hematopoietic Stem Cell
10%
Cell Transplantation
10%
CD20
10%
Acute Leukemia
9%
Chronic Myelogenous Leukemia
8%
Cancer Cell
8%
Hepatitis C
8%
Homeostasis
8%
Neoplasm
8%
Multiple Myeloma
8%
Acute Myelogenous Leukemia
8%
Prednisone
8%
Keyphrases
Acute Myeloid Leukemia
99%
COVID-19
35%
Leukemia Patients
32%
Minimal Residual Disease
30%
Decitabine
28%
Older Patients
28%
Acute Promyelocytic Leukemia
23%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
17%
Hematology
16%
Intensive Chemotherapy
15%
Overall Survival
15%
Leukemia Risk
14%
Pemphigus Vulgaris
14%
Adult Acute Lymphoblastic Leukemia
14%
Molecular Diagnostics
14%
Nucleophosmin 1 (NPM1)
14%
B-cell Lymphoma 2 (Bcl-2)
14%
Flow Cytometry
12%
High Risk
12%
Myelodysplastic Syndrome
11%
Chemotherapy
11%
Rituximab
9%
Prognostic Relevance
9%
COVID-19 Infection
9%
Comorbidity
9%
All-trans Retinoic Acid
9%
FMS-like Tyrosine Kinase 3 (FLT3)
9%
AZD1775
8%
Improved Outcomes
8%
Complete Remission
8%
Chronic Lymphocytic Leukemia
8%
COVID-19 Pandemic
8%
Multiple Myeloma
8%
B Cells
8%
Hematological Malignancies
8%
Clinical Trials
8%
Drug Sensitivity
8%
Post-remission Therapy
7%
Risk Stratification
7%
Mutational Status
7%
Monoclonal Antibody
7%
DNA Damage
7%
Conventional Chemotherapy
7%
Salvage Therapy
7%
Oncoprotein
7%
FLT3 Internal Tandem Duplication
7%
Breakthrough COVID-19
7%
Primary Myelofibrosis
7%
Angioimmunoblastic
7%
Primary Hepatic Lymphoma
7%